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MCV, BK virus and JC virus, have long been associated with serious diseases including
polyomavirus nephropathy and progressive multifocal leukoencephalopathy. Both viruses establish
ubiquitous, persistent infections in healthy individuals. Reactivation can occur when the immune system
is impaired, leading to disease progression. Recently, the human polyomavirus family has expanded with the
identiﬁcation of three new viruses (KI, WU and Merkel cell polyomavirus), all of which may prove to be
involved in human disease. This review describes the general aspects of human polyomavirus infections and
pathogenicity. Current topics of investigation and future directions in the ﬁeld are also discussed.
© 2008 Elsevier Inc. All rights reserved.Discovery of human polyomaviruses
The ﬁrst human polyomaviruses, BK virus (BKV) and JC virus (JCV),
were coincidently isolated in 1971 by two independent groups, BKV
from the urine of a renal transplant patient who suffered from ureteral
stenosis (Gardner et al., 1971) and JCV from the brain tissue of a patient
with Hodgkin's lymphoma who developed progressive multifocal
leukoencephalopathy (PML) (Padgett et al., 1971). Nearly four decades
passed before DNA sequences representing three newmembers of the
human polyomavirus family were discovered. Viral genomes cloned
from these sequences have been designated KI polyomavirus (KI), WU
polyomavirus (WU), and Merkel cell polyomavirus (MCV). KI and WU
were identiﬁed from large-scale high-throughput screens of respira-
tory secretions from patients with respiratory tract infections
(Allander et al., 2007; Gaynor et al., 2007), and MCV was identiﬁed
in Merkel cell carcinomas (MCC) using digital transcriptome subtrac-
tion (Feng et al., 2008). The human polyomaviruses have a tradition of
nomenclature based on the origin of the isolate: BKV and JCV take
their names from the initials of the patients from whom they were
isolated, while KI andWU are named after the institutions where they
were discovered. Only MCV departs from this convention as it is
named after the type of tumor from which it was identiﬁed. Thisand Immunology, University of
e, 5724 Medical Science II, Ann
).
l rights reserved.review will focus on BKV and JCV, whose roles as human pathogens
are best understood.
General aspects of polyomavirus infection
The human polyomaviruses, as with all polyomaviruses, are
composed of small, non-enveloped, icosahedral virions with a super-
coiled double-stranded DNA genome (Imperiale and Major, 2007). The
virion consists of 72 pentamers of the major capsid protein VP1, with
each pentamer associated with a single copy of the minor capsid
protein VP2 or VP3 (Liddington et al.,1991; Stehle et al., 1996). The viral
genome is associated with cellular histones to form a so-called
minichromosome, the structure of which is similar to host chromatin
(Meneguzzi et al., 1978; Muller et al., 1978). Polyomaviruses are known
to have very restricted host ranges; accordingly, BKV and JCV are only
known to productively infect and cause disease in humans.
The genomes of BKVand JCVaredivided into three regions: the early
coding region, which encodes the large tumor antigen (TAg) and small
tumor antigen (tAg); the late coding region, which encodes the viral
capsid proteins VP1, VP2 and VP3, and the nonstructural agnoprotein;
and the non-coding control region (NCCR), which contains the viral
promoters and origin of replication. These viruses also encode auxiliary
T antigens that are derived from alternative splicing of the TAg
transcript (Bollag et al., 1989; Trowbridge and Frisque, 1995). KI and
WUshare themost signiﬁcant homologywithBKVand JCV in regards to
genome organization and amino acid sequence of predicted viral
proteins (Allander et al., 2007; Gaynor et al., 2007). MCV on the other
hand is most similar to the African green monkey lymphotropic
polyomavirus (LPV) (Feng et al., 2008).
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267MinireviewRoute of transmission and seroconversion
The mode of transmission for BKV and JCV is not yet well deﬁned,
however, evidence suggesting respiratory transmission is present in
the literature. A study of children with respiratory diseases showed
that a high percentage of tonsillar tissues contained nonintegrated
forms of BKV DNA (Goudsmit et al., 1982). Similarly, the presence of
JCV DNA in B cells and stromal cells of the tonsils and oropharynx
supports this hypothesis (Monaco et al., 1998a). Seroconversion for
both viruses is widespread and occurs in childhood, with BKV
seropositivity reaching 90% in children aged 5 to 9 and JCV
seropositivity reaching 50 to 60% after the age of 10 (Knowles,
2006). Potential alternative modes of transmission for these viruses
include urino-oral, transplancental, and transmission by blood
transfusion, semen and organ transplantation (Boﬁll-Mas et al.,
2001; Boﬁll-Mas et al., 2000; Hirsch and Steiger, 2003).
Adult seroprevalence for BKV and JCV is very high:more than 90% of
the adult population is seropositive for BKV (Knowles et al., 2003),
while 50 to 80% of adults have antibodies to JCV (Khalili et al., 2007;
Knowles, 2006). Interestingly, the antibody titer against BKV decreases
as the age increases, while that of JCV remains relatively unchanged
(Knowles, 2006; Knowles et al., 2003). In addition, there is a negative
association between the seropositivity of BKV and JCV, with BKV
seronegative individuals more likely to be JCV seropositive, suggesting
that these two viruses may either be transmitted through different
mechanisms or that infection with BKV may provide some protective
effects against JCV (Knowles et al., 2003; Taguchi et al., 1982).
Dissemination and persistence
Primary infections with BKV and JCV are typically subclinical or
linked tomild respiratory illness (Goudsmit et al.,1981; Goudsmit et al.,
1982), and are followed by viral dissemination to the sites of lifelong
persistent infection. Themajor sites of persistence for both BKV and JCV
are the cells of the kidney and urinary tract (Chesters et al., 1983;
Heritage et al., 1981). BKV DNA has been found in 30 to 50% of normal
kidney tissues, with distribution patterns of small foci throughout the
cortex andmedulla, and in 40% of ureters (Monini et al., 1995; Nickeleit
et al., 2003). In addition, BKV-speciﬁc immunostaining analyses
identiﬁed epithelial cells of the kidney, ureter and bladder as the
predominant cell types that are persistently infected (Shinohara et al.,
1993). JCV DNA can be detected in approximately 10 to 50% of normal
kidney samples, although at lower levels than BKV DNA (Aoki et al.,
1999; Chesters et al., 1983; Grinnell et al., 1983). Numerous reports of
JCV DNA in lymphocytes argue for the importance of these cells in
persistence and dissemination via circulatory routes (Doerries, 2006;
Doerries et al., 1994, 2003; Monaco et al., 1996, 1998b; Tornatore et al.,
1992). It is not known whether the viruses enter a latent state or
maintain a low level of viral gene expression and replication at these
sites, although intermittent replication must occur as evidenced by
periodic excretion of virus in the urine. Approximately 5% of
immunocompetent individuals have BKV viruria while 20 to 30% are
actively shedding JCV (Doerries, 2001; Knowles, 2001). In addition,
asymptomatic viruria has been observed in approximately 3% of
pregnant women during the second and third trimesters (Arthur and
Shah, 1989; Chang et al., 1996b; Coleman et al., 1980; Markowitz et al.,
1991). How the host innate, humoral, and cellular immune responses
control these persistent infections remains unknown.
A variety of other cell types have been reported to contain BKV and
JCV sequences, and it has been suggested that infection of these cells
may be involved in dissemination or persistence. BKV sequences have
been detected at a high frequency in urogenital tissues and ﬂuids
including cervix, vulva, prostate, and semen, and a relatively lower
frequency in brain tissues, consistent with its urotheliotropic nature
(Doerries, 2006; Elsner and Dorries, 1992; Martini et al., 2004; Monini
et al., 1996; Monini et al., 1995; Pietropaolo et al., 2003). Moreover,BKV DNA has been found in peripheral blood mononuclear cells and
spleen (Chatterjee et al., 2000; Dorries et al., 1994; Pietropaolo et al.,
2003), suggesting the involvement of the immune system in BKV
spread. Additionally, endothelial cells have been shown to support
BKV replication in vitro, raising the possibility that BKV may cross the
endothelial barrier to disseminate from the periphery to its target
organs via blood (Hanssen Rinaldo et al., 2005). There are rare reports
of JCV sequence detection in various tissues and cells including the
liver, lung, spleen, lymph nodes, and colorectal epithelium (Caldarelli-
Stefano et al., 1999; Doerries, 2001; Grinnell et al., 1983; Laghi et al.,
1999; Newman and Frisque, 1997; Newman and Frisque, 1999). While
JCV reactivation leads primarily to infection of the brain, it is unclear
whether normal brain tissue harbors the virus (Doerries, 2001). Many
researchers have reported the presence (Caldarelli-Stefano et al., 1999;
Elsner and Dorries, 1992; Mori et al., 1992) or absence (Chesters et al.,
1983; Quinlivan et al., 1992; Stoner et al., 1988) of JCV sequences in the
brains of patients without PML. Overall, however, these studies are
small with signiﬁcant variation in the health conditions of the
individuals.
Reactivation during immunosuppression
Human polyomaviruses cause signiﬁcant disease primarily in
individuals that are immunocompromised, allowing reactivation
from the persistent subclinical state to a lytic infection resulting in
viruria and viremia, potentially leading to severe or fatal diseases
(Table 1).
For BKV, reactivation is most common in bone marrow transplant
(BMT) and renal transplant patients,where BKV lytic infection results in
hemorrhagic cystitis (HC) and polyomavirus nephropathy (PVN),
respectively. In addition, reactivation has been observed in individuals
with altered immune conditions including other solid organ trans-
plantations, autoimmune diseases such as systemic lupus erythema-
tosus (SLE), and patients with acquired immunodeﬁciency syndrome
(AIDS) (Chang et al., 1996a; Munoz et al., 2005; Sundsfjord et al., 1999).
The levels of BKV viruria correlate with the degree of immunosuppres-
sion, indicating that viral replication results from the reactivation of a
persistent infection rather than reinfection (Ahsan and Shah, 2006;
Doerries, 2001). In patients with SLE, it has also been suggested that
BKV infection might initiate autoimmunity by inducing antibodies
against DNA and histones (Rekvig et al., 1997). In the context of HIV
infection, BKV viruria has been shown to increase concomitantlywith a
decrease in CD4+ T cell counts (Gluck et al., 1994; Knowles et al., 1999).
Although very rare, BKV has also been linked to meningoencephalitis,
retinitis, and lung infection inAIDSpatients and individuals undergoing
immunosuppression (Bratt et al.,1999; Cubukcu-Dimopulo et al., 2000;
Vallbracht et al., 1993).
The most common underlying cause of immunosuppression
leading to JCV reactivation is AIDS. Reactivation results in the lytic
infection of oligodendrocytes in the brain and the development of
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been reported include lymphoproliferative diseases such as lympho-
mas and leukemias, myeloproliferative diseases, transplantation,
chemotherapy, multiple sclerosis (MS), and inherited immunodeﬁ-
ciences (Berger, 2003; Berger and Concha, 1995; Brooks and Walker,
1984). In contrast to observations with BKV, JCV viruria does not
correlate with the degree of immunosuppression (Doerries, 2001),
indicating the importance of other factors during reactivation.
Polyomavirus-associated diseases
BK virus and polyomavirus nephropathy
PVN, the most frequent BKV-associated disease after renal
transplantation, is a form of acute interstitial nephritis (Nickeleit and
Mihatsch, 2006). BKV viruria and viremia due to reactivation are found
in up to 80% of renal transplant patients and 10% of patients progress to
PVN, resulting in allograft loss 90% of the time (Binet et al., 1999;
Bressollette-Bodin et al., 2005; Egli et al., 2007; Hirsch et al., 2002).
PVN is characterized by necrosis of proximal tubules anddenudationof
the basement membrane as a result of BKV lytic infection in kidney
epithelial cells (Nickeleit et al., 2003). Recently, the incidence of PVN
has been rising with the introduction of new and more potent
immunosuppressive regimens (Binet et al., 1999; Mengel et al., 2003;
Nickeleit et al., 2000), indicating a relationship between BKV
reactivation and the disruption of the immune system. The current
standard of diagnosis of PVN includes analysis of renal biopsies using
histopathology or immunohistochemistry, either to detect cytopathic
changes as a result of injury or lysis of renal tubular epithelial cells, or
to detect viral gene expression. In addition, urine cytology is used to
detect decoy cells, which are epithelial cells with intranuclear viral
inclusion bodies, and PCR to detect viral genomes and quantify viral
load in blood or urine samples (Drachenberg et al., 2005; Vats et al.,
2006). PCR and urine cytology may be more useful for detecting the
early stages of reactivation and PVN (Hirsch et al., 2002; Ramos et al.,
2002b), thus allowing for faster diagnosis and intervention, with a
consequent increase in graft survival (Drachenberg et al., 2004).
There is no single risk factor associated with the development of
PVN. Instead it is thought that what determines susceptibility to BKV
reactivation is a combination of contributing factors from the virus,
patient, and graft. The overall degree of immunosuppression, and not
the particular immunosuppressive drugs employed, is suggested to be
the major risk factor for PVN (Bonvoisin et al., 2008). Impairment of
the immune system alone, however, is not sufﬁcient for the
development of PVN, as the disease manifestation is relatively
uncommon in nonrenal solid organ transplant and other immuno-
suppressed patients (Hirsch, 2005; Pavlakis et al., 2006). Other
suggested risk factors include donor seropositivity, speciﬁc HLA
locus or HLA mismatches, anti-rejection treatment, older age, and
male gender (Bohl et al., 2005; Hirsch et al., 2002; Ramos et al., 2002a;
Ramos et al., 2002b).
The immune response to BKV during PVN is an active area of
investigation. A critical question that arises is what facet of the
immune response is important for maintaining control over infection.
The humoral response does not appear to be sufﬁcient to restrict BKV
infection, as it is reported that approximately 70% of patients are
seropositive for BKV before renal transplantation (Hirsch et al., 2002)
and that individuals with detectable anti-BKV antibodies still progress
to PVN (Comoli et al., 2006). Instead, it seems that antibodies aremore
indicative of the viral load in a patient rather than protection against
BKV infection, as high levels of antibodies in PVN patients correlate
with high levels of viremia and low CD8+ T cell responses (Chen et al.,
2006). The cell-mediated immune response may be more relevant to
disease development: low levels of BKV-speciﬁc interferon (IFN)-γ-
producing T cells correlate with progression to PVN, while reconstitu-
tion of these cells correlates with resolution of PVN (Binggeli et al.,2007; Chen et al., 2006; Prosser et al., 2008). Moreover, in vitro studies
have demonstrated that IFN-γ strongly inhibits BKV replication in
kidney epithelial cells (Abend et al., 2007). Therefore, it is suspected
that the effector functions and cytokines produced by T cells may be a
crucial means to control BKV replication and reactivation.
At this time, effective and speciﬁc anti-viral treatments for BKV do
not exist: the most common initial intervention is to decrease
immunosuppression to allow the host immune system to regain
control over the infection. This, however, leaves the patients at risk for
acute graft rejection and is not effective in all patients. Cidofovir is an
antiviral nucleoside analog which is known to inhibit BKV DNA
replication (Bernhoff et al., 2008), but can be nephrotoxic at high
doses (Blanckaert and De Vriese, 2006). There are some recent
indications, however, that when this drug is used at low doses and in
combination with a reduction in immunosuppression, it may be
effective against BKV reactivation without causing signiﬁcant nephro-
toxicity (Bjorang et al., 2002; Kadambi et al., 2003; Kuypers et al.,
2005). In addition, there has been some limited success with
leﬂunomide, an immunosuppressive drug (Faguer et al., 2007;
Josephson et al., 2006; Williams et al., 2005). Other antiviral
treatments that have been used in clinical trials include intravenous
immunoglobulin (IVIG) and ﬂuoroquinolone antibiotics (Bonvoisin et
al., 2008; Rinaldo and Hirsch, 2007; Sener et al., 2006; Sessa et al.,
2008). However, more systematic studies are warranted to evaluate
the efﬁcacies of these treatments. Finally, retransplantation following
nephrectomy, to rapidly clear the viral source, is another therapeutic
approach (Funk et al., 2006; Poduval et al., 2002).
BK virus and hemorrhagic cystitis
HC is a serious BKV-associated complication characterized by
dysuria and varying degrees of hematuria that affects up to 10% of BMT
patients (Dropulic and Jones, 2008). The ﬁrst association of BKV
reactivation with HC was reported in the late 1970s and was further
established in the 1980s (Arthur et al., 1985; Hashida et al., 1976;
Mininberg et al., 1982). HC is likely due to viral reactivation in the
urothelium, as BKV virions can be detected in exfoliated epithelial
cells (Fogazzi et al., 2001; Hiraoka et al., 1991). Moreover, the level of
viruria correlates with the development of HC (Arthur et al., 1986;
Bogdanovic et al., 2004). Typically, BKV-associated HC occurs more
than 10 days post-transplant (late-onset) and requires medical
attention: while not usually life-threatening, HC is associated with
signiﬁcantmorbidity (Apperley et al., 1987; Azzi et al., 1999; Bedi et al.,
1995; Egli et al., 2007). Urine cytology and PCR detection of viral DNA
are themost commonly usedmethods for diagnosis of BKV-associated
HC (Dropulic and Jones, 2008). As with PVN, antivirals such as
cidofovir and ﬂuoroquinolone antibiotics are currently being tested
for their effectiveness in treating BKV-associated HC (Held et al., 2000;
Leung et al., 2005; Savona et al., 2007).
JC virus and progressive multifocal leukoencephalopathy
PMLwas originally described in 1958 as a demyelinating disease of
the central nervous system (Astrom et al., 1958), and later viral
particles were detected by electron microscopy in the brains of
patients with PML (Silverman and Rubinstein, 1965; Zurhein and
Chou,1965). It became apparent that JCV infection is the cause of PML,
as essentially all brain and cerebrospinal ﬂuid (CSF) samples from
these affected patients have detectable levels of JCV DNA and proteins
(Gibson et al., 1993; Grinnell et al., 1983; Stoner et al., 1986; Taouﬁk et
al., 1998). Initially, PML was a fairly rare malady associated with
immunosuppressed patients, primarily those with lymphomas and
leukemias (Johnson, 1982; Walker, 1985). With the rise of the AIDS
epidemic, however, JCV infections resulting in PML have risen
dramatically. The majority (55 to 85%) of PML cases occur in patients
with AIDS (Berger and Nath, 2001; Major et al., 1992), with only
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disorder (Brooks and Walker, 1984; Safak and Khalili, 2003). As such,
PML is now considered an AIDS-deﬁning illness (Stoner et al., 1986).
Approximately 6% of HIV cases have JCV replication in the kidneys and
approximately 5% of individuals with HIV develop PML (Berger, 2003;
Berger and Concha, 1995; Boldorini et al., 2003; Stoner et al., 1986).
Clinically, PML is characterized by impaired speech and vision,
dementia or confusion, and varying degrees of paralysis or akinesia, in
conjunctionwith an immunocompromised state and a lack of increase
in intracranial pressure (Berger and Concha, 1995; Brooks andWalker,
1984). The subsequent disease progression is rapid, with clinical
symptoms intensifying and death of the patient within 3 to 6 months
(Berger et al., 1998). At the cellular level, PML is a cytolytic infection of
oligodendrocytes, the myelin producing cells of the brain. Infection
results in cell death and development of lesions in the cerebrum,
cerebellum and brain stem, particularly along the junction of the gray
and white matter (Berger and Major, 1999; Whiteman et al., 1993).
Neurons are not affected and astrocytes can be infected nonpermis-
sively, only expressing TAg and not progressing to cell lysis (Aksamit,
1995; Berger and Concha, 1995; Johnson, 1982). In addition, JCV
sequences have been detected in other cells within the brain including
B cells and mononuclear cells (Hou et al., 2006; Houff et al., 1988;
Major et al., 1990; von Einsiedel et al., 2004). Other characteristics of
PML include enlarged JCV TAg-expressing oligodendrocytes with
nuclear inclusion bodies and crystalline arrays of viral particles, an
increasing presence of macrophages, and enlarged, so-called bizarre
astrocytes with lobulated, hyperchromatic nuclei (Berger and Nath,
2001; Major et al., 1992). The widespread distribution of brain lesions
and the high frequency of JCV-positive peripheral blood cells suggest
that lymphocytes can serve as a reservoir and dissemination vehicle
(Jensen and Major, 1999; Koralnik et al., 1999b; Major et al., 1992). It is
not clear if JCV infection of the brain is a result of de novo invasion of
the virus or reactivation of a persistent infection (Doerries, 2006;
White et al., 1992). PML patients, however, do not have enhanced
viruria and renal infection as compared to healthy controls (Arthur
and Shah, 1989; Doerries, 2001; Koralnik et al., 1999a).
The underlying cause for the association between JCV-associated
PML and HIV/AIDS is not fully understood. Several hypotheses may
explain the link between these two virus-associated diseases (Berger,
2003; Berger et al., 2001; Khalili et al., 2006; Seth et al., 2003). First,
HIV establishes a state of profound immunosuppression within the
host, and speciﬁcally, a decrease in JCV-speciﬁc CD4+ T cells as a result
of HIV infection could allow uncontested replication of JCV. More
directly, HIV infection may result in breakdown of the blood-brain
barrier, allowing entry of JCV-harboring B cells into the brain.
Furthermore, production of certain cytokines in response to HIV
infection may initiate signaling within the cell that results in
activation of the JCV promoter. Finally, there is some evidence that
the HIV Tat protein is able to act on JCV promoters in vitro and
promote gene expression (Chowdhury et al., 1992; Tada et al., 1991). In
support of this observation, HIV Tat and JCV VP1 expression have been
detected in the same areas of the brain that are affected by PML (Del
Valle et al., 2000).
The cell-mediated immune response, inparticular Tcells, appears to
be very important for controlling JCV infections. Studies have shown
that patients with higher levels of JCV-speciﬁc CD4+ and CD8+ T cells
have prolonged survival (Berger et al., 1998; Gasnault et al., 2003;
Koralnik, 2006). Anti-JCV antibody levels do not change during
progression of PML and are not detected in the CSF, arguing against
the involvement of the humoral immune response. Early detection and
various therapeutic interventions, including chemotherapy, nucleoside
analogs, receptor blockers, and IFN-α, have not been effective at
increasing survival time (Roskopf et al., 2006). Highly active antire-
troviral therapy (HAART), however, has improved the survival of
patients to approximately 10.5months post-onset of clinical symptoms
(Cinque et al., 2001; Clifford et al., 1999; De Luca et al., 2000).JC virus and multiple sclerosis
While MS and PML are both diseases resulting in demyelinated
lesions of the brain, they are distinguished by the morphologically-
distinct bizarre astrocytes, inclusion bodies within the nuclei of
oligodendrocytes, and the lack of inﬂammatory inﬂitrates, which are
characteristic of PML (Khalili et al., 2007). Still, the similarities
between these conditions have prompted an investigation of the
association of MS with JCV reactivation and PML. There are conﬂicting
reports of JCV DNA and viremia in patients with MS: several studies
report a lack of evidence for JCV infection in MS patients (Bogdanovic
et al., 1998; Buckle et al., 1992), while others have found JCV DNA
sequences in CSF of some MS patients but not in healthy controls
(Ferrante et al., 1998; Koralnik et al., 1999a).
Recently, there have been two cases of PML in MS patients treated
in the same clinical trial with a combination therapy of natalizumab
(Tysabri), anα4β1 integrin inhibitor that prevents Tcell trafﬁcking into
the brain, and IFN-β-1A (Avonex) (Kleinschmidt-DeMasters and Tyler,
2005; Langer-Gould et al., 2005). A third case of PMLwas reported in a
patient with Crohn's disease who was also treated with natalizumab
(Van Assche et al., 2005). These results suggest that restricting T cell
entry into the brain allows reactivation of JCV and development of
PML. Further examination of patients undergoing therapy with
natalizumab indicated no clear association between PML and
treatment: out of 3417 patients treated with natalizumab, only 44
were suspected of having PML and none of these cases were
conﬁrmed (Yousry et al., 2006).
Human polyomaviruses and cancer
There is no clear association between BKV and JCV and the
development of tumors. Various reports have indicated the presence
or absence of viral genomic sequences in multiple human cancers. It
has been suggested that that BKV is associated with brain tumors,
adenocarcinomas, prostate cancers, and bladder carcinomas, and JCV
is associated with mesotheliomas, brain tumors, osteosarcomas, and
lymphomas. For a more detailed discussion about the association of
human polyomaviruses with cancer, refer to the following reviews
(Barbanti-Brodano et al., 2006; Khalili et al., 2006; Lee and Langhoff,
2006) and this issue of Virology.
KI, WU, MCV, and human disease
Since KI and WU were ﬁrst identiﬁed, viral sequences have been
conﬁrmed in respiratory specimens worldwide (Abed et al., 2007;
Abedi Kiasari et al., 2008; Bialasiewicz et al., 2008; Bialasiewicz et al.,
2007; Han et al., 2007; Le et al., 2007; Lin et al., 2008; Neske et al.,
2008; Norja et al., 2007; Payungporn et al., 2008), suggesting both
viruses are widespread among human populations. Furthermore,
available data support a model in which primary infection with KI or
WU occurs during childhood (Abedi Kiasari et al., 2008; Bialasiewicz
et al., 2007; Gaynor et al., 2007). Despite their clear presence in
specimens of patients with respiratory illnesses, the pathogenicity of
KI and WU remains speculative. The proposed association of KI and
WU with respiratory disease is tenuous because the majority of
studies to date have not included specimens from asymptomatic
patients. In the three studies that included these control groups, viral
sequences were detected at similar frequencies in asymptomatic
patients (Abed et al., 2007; Han et al., 2007; Norja et al., 2007). The
link between KI and WU infection and respiratory disease is further
complicated by the high rates of co-infection with other respiratory
viruses that were observed in these studies (Abedi Kiasari et al.,
2008; Allander et al., 2007; Bialasiewicz et al., 2008; Gaynor et al.,
2007; Han et al., 2007; Le et al., 2007; Neske et al., 2008). Despite the
lack of evidence for KI and WU causing disease, more research is
warranted to investigate this possibility, especially considering their
270 Minireviewsimilarities to BKV and JCV in nucleotide sequence and potential
route of infection.
MCV, the most recently discovered human polyomavirus, has been
implicated in the etiology of MCC (Garneski et al., 2008; zur Hausen,
2008), a rare but aggressive form of skin cancer. Feng et al. (2008)
identiﬁed sequences corresponding to MCV in 8 of 10 MCC tumors, as
compared to 5 of 59 control tissues. Viral DNA in 6 of the 8 MCC
positive tumors showed a clonal integration pattern. One tumor had
similar primary and metastatic integration patterns, suggesting viral
integration preceded metastasis. Interestingly, the integrated form of
MCV in these tumors is predicted to encode a truncated TAg due to
mutations within the second exon of the TAg gene. This truncation
would result in the loss of TAg domains required for viral DNA
replication and p53 binding but does not affect domains required for
inducing cell-cycle progression, suggesting this predicted protein may
retain its transformation capability. Subsequent studies have con-
ﬁrmed the presence of MCV sequences in MCC tumors at similar
frequencies as the original study (Becker et al., in press; Foulongne et
al., 2008; Garneski et al., in press; Kassem et al., 2008). Despite the
presence of MCV in signiﬁcant numbers of Merkel cell tumors, the
involvement of this virus in the development of MCC is still uncertain.
More studies are required to determine if MCV integration or potential
expression of oncogenic viral T antigens contributes to MCC.
Unanswered questions in human polyomavirus pathogenesis
While we understand much of the molecular biology of human
polyomaviruses, basic questions about the viruses themselves and
their interactions with the host remain unanswered. First, it is unclear
how the viruses spread throughout the population. While it is
apparent that BKV and JCV are shed in urine, their detection in
tonsillar lymphocytes could be indicative of transmission via the
respiratory route. In addition, it is curious that children seroconvert
against BKV at an earlier age than against JCV. One of the most
important questions is how the viruses persist in healthy individuals.
The answer to this question will require more information on the
biology of BKV and JCV in the urinary tract as well as a better
understanding of the immune components responsible for controlling
viral replication. It is not known whether the viruses undergo some
low level of ongoing replication, as evidenced by periodic excretion
into the urine, or establish a true latent state. It will also be important
to determine whether the cells in which BKV and JCV persist are the
same as or different from those in which they replicate to cause
disease. To pursue studies of the immune responses to these viruses,
researchers may have to rely on an animal model using mouse
polyomavirus, although the genetic structure of this virus differs
signiﬁcantly from that of the human viruses in that it encodes a
different cadre of Tantigens. Lastly, the changes in the host that lead to
reactivation must be uncovered in more detail. Clearly immunosup-
pression plays a major role in reactivation, but not all AIDS patients
present with PML and not all transplant patients present with PVN,
despite being on the same immunosuppressive regimen. The available
evidence suggests that these differences are not due to genetic
variation in the viruses themselves. Thus, one must invoke poly-
morphisms in the human population that affect tropism or perhaps
the immune response. Rapid advances in genetics may allow the
deﬁnition of host gene(s) that determine susceptibility to BKV and JCV
reactivation.
For the newly discovered polyomaviruses, some very basic
questions must be answered. First and foremost, can infectious
MCV, WU, and KI particles be isolated and grown in the laboratory?
An experimental system for the propagation of these viruses will be
essential to understand their biology. It will also be important to
determine if these viruses persist in the urinary tract like JCV and BKV,
or if they are only associated with acute infections or cancers.
Furthermore, routes of transmission and epidemiology of KI, WU, andMCV will need to be determined. For MCV, it will be interesting to
know if there is selection in MCC for variants that express truncated
forms of TAg, and if there is anything unique about Merkel cells that
makes them susceptible to oncogenesis by this virus. A related
question in the polyomavirus ﬁeld is whether SV40 is a human
pathogen. This question is highly controversial and there are contra-
dictory reports in the literature, with some groups ﬁnding viral
sequences in various human tumors while other groups failed to
detect sequences in the same type of tumor (Garcea and Imperiale,
2003). To date, there is no good serological evidence for SV40 in
humans (Carter et al., 2003; Shah et al., 2004) although this does not
prove that SV40 is not a human pathogen (Vilchez and Butel, 2004).
This long-standing controversy needs resolution since a large number
of people were exposed to SV40 in contaminated poliovirus vaccines,
and it remains possible that the virus could spread from human to
human (Stratton et al., 2002). The recent discoveries of new human
polyomaviruses certainly raise the question of whether there are
additional viruses in the population and have rekindled interest in
previously-identiﬁed viruses. For example, there is serologic evidence
for LPV infection of humans (Brade et al., 1981; Viscidi and Clayman,
2006; R. Garcea, personal communication). Although current virus
discovery attempts are mainly aimed at isolating pathogens from sick
individuals, it is possible that there are viruses that are not associated
with disease but simply persist and spreadwithout clinical symptoms.
Given the increasing incidenceof polyomavirus-associateddiseases,
particularly the severe diseases in immunocompromised individuals,
there is a dire need for more effective and speciﬁc antivirals. Cidofovir
shows some efﬁcacy but can be nephrotoxic, limiting its utility,
especially in renal transplant patients. Candidate targets include
small molecules that interfere with TAg function or virion assembly,
which could be identiﬁed using high-throughput screens. One must
also consider whether vaccine development is plausible; the success of
the human papillomavirus vaccines, along with the fact that polyo-
mavirus virus-like particles are easily produced, is supportive of the
possibility of vaccination.
For many years, much effort was focused on SV40 as a model
system for understanding basic eukaryotic processes such as tran-
scription, DNA replication, and oncogenic transformation, while
studies of the human polyomaviruses and their roles as human
pathogens took a back seat. Since polyomaviruses are highly adapted
to their own hosts, each virus must be studied and understood as
individual entities. Future studies hold great promise for the ability to
detect and combat these important and ubiquitous viruses.
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